Medpro Pharmaceutica Pty Limited Pharmaceutical Import Profile — South Africa (DGFT 2022–2026)

Name: Medpro Pharmaceutica Pty Limited Pharmaceutical Import Records from India — 13 Products, $24.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medpro Pharmaceutica Pty Limited — Pharmaceutical Importer Profile (2026) | 13 Products, $24.1M Trade | TransData Nexus

Medpro Pharmaceutica Pty Limited

Pharmaceutical Importer · South Africa · Respiratory Focus · $24.1M Total Trade · DGFT Verified

Medpro Pharmaceutica Pty Limited is a pharmaceutical importer based in South Africa with a total trade value of $24.1M across 13 products in 7 therapeutic categories. Based on 520 verified import shipments from Indian Customs (DGFT) records, Medpro Pharmaceutica Pty Limited is the #1 buyer in 2 products including Salbutamol, Ipratropium. Medpro Pharmaceutica Pty Limited sources from 4 verified Indian suppliers, with Cipla Limited accounting for 95.5% of imports.

Medpro Pharmaceutica Pty Limited — Import Portfolio & Supplier Network

Medpro Pharmaceutica Pty Limited import network — 13 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Medpro Pharmaceutica Pty Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$12.9M	836	95.5%
Serum Institute Of India Private Limited	$386.1K	9	2.9%
Intas Pharmaceuticals Limited

What Formulations Does Medpro Pharmaceutica Pty Limited Import?

Formulation	Value	Ships
Asthavent ecohaler salbutamol	$718.1K	22
Venlor xr capsules 150MG venlafaxine	$550.0K	11
Cipla warfarin 5MG tabs warfarin	$508.5K	18
Beclate 200mcg hfa inhaler	$459.2K	10
Flomist nasal spray fluticasone propionate nasal suspension 50mcgpack size:1x120	$450.0K	9
Flomist nasal spray fluticasone propionate nasal suspension 50mcgpack size	$450.0K	9
Flomist nasal spray fluticasone	$400.0K	8
Damicava tablet abacavir 600MG +	$385.3K	8
Uromax 0.4MG capsules tamsulosin	$255.0K	7
Asthavent 200md cfc free inhaler	$253.7K	7
Lopimune 40/10 oral pellets lopinavir	$250.0K	5
Budeflam 100 inhaler with	$213.7K	6
Sereflo 25/125 hfa inhaler with gentle	$200.0K	4
Nuzak 20MG capsules fluoxetine	$200.0K	4
Beclate 200mcg hfa inhaler beclomethasone dipropionate 200mcg Pack	$189.7K	4

Medpro Pharmaceutica Pty Limited imports 290 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 13 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Salbutamol	Respiratory	$10.5M	216	6.2%	1
2	Fluticasone	Respiratory	$6.7M	145	1.6%	7
3	Ipratropium	Respiratory	$1.9M	38	2.6%	1
4	Salmeterol	Respiratory	$1.4M	27	1.9%	12
5	Warfarin	Cardiovascular	$1.2M	42	6.9%	3
6	Nifedipine	Cardiovascular	$670.9K	15	2.2%	7
7	Lansoprazole	Gastrointestinal	$500.0K	10	0.2%	13
8	Imatinib	Advanced Oncology	$300.0K	6	1.0%	9
9	Sertraline	CNS & Psychiatric	$300.0K	6	0.1%	15
10	Teicoplanin	Advanced Antibiotics	$209.1K	6	3.3%	6
11	Atazanavir	Antiviral & HIV Medications	$200.0K	4	0.3%	8
12	Bleomycin	Advanced Oncology	$150.0K	3	2.7%	4
13	Erlotinib	Advanced Oncology	$78.8K	2	2.9%	9

Medpro Pharmaceutica Pty Limited imports 13 pharmaceutical products across 7 categories into South Africa totaling $24.1M. The company is the #1 buyer for 2 products: Salbutamol, Ipratropium.

Medpro Pharmaceutica Pty Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Medpro Pharmaceutica Pty Limited is a prominent pharmaceutical importer and distributor based in South Africa. The company specializes in sourcing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. With a total import value of $24.1 million USD over 520 shipments, Medpro Pharmaceutica imports 13 products across seven therapeutic categories. The company's top five imported products are Salbutamol ($10.5 million, 6.2% share), Fluticasone ($6.7 million, 1.6% share), Ipratropium ($1.9 million, 2.6% share), Salmeterol ($1.4 million, 1.9% share), and Warfarin ($1.2 million, 6.9% share). Notably, Medpro Pharmaceutica is the leading buyer of Salbutamol and Ipratropium in the South African market. The company's portfolio is highly concentrated, with the top five products accounting for 90% of its total imports.

2Distribution Network

Medpro Pharmaceutica operates a robust distribution network within South Africa, ensuring efficient delivery of pharmaceutical products nationwide. While specific warehouse locations are not publicly disclosed, the company maintains a significant presence in Cape Town, with offices located at Parc Du Cap Office Park, Building 9, Mispel Street, Bellville, Cape Town, 7530. This strategic location facilitates effective logistics and distribution across the country. The company's logistics capabilities are designed to handle a diverse range of pharmaceutical products, ensuring timely and secure delivery to various healthcare providers and institutions.

3Industry Role

In South Africa's pharmaceutical supply chain, Medpro Pharmaceutica Pty Limited functions as a primary wholesaler and distributor. The company imports finished pharmaceutical formulations from international suppliers, particularly from India, and distributes these products to various stakeholders within the healthcare sector. By focusing on finished products, Medpro Pharmaceutica plays a crucial role in ensuring the availability of essential medicines in the South African market, thereby contributing to the overall healthcare infrastructure.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Medpro Pharmaceutica Pty Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Medpro Pharmaceutica's sourcing strategy exhibits a high degree of concentration, with the top five imported products accounting for 90% of its total imports. This concentration indicates a strategic focus on high-demand therapeutic areas, particularly in respiratory and cardiovascular treatments. The company's reliance on a limited number of products may streamline operations and strengthen supplier relationships. However, this approach also exposes Medpro Pharmaceutica to potential risks associated with supply chain disruptions or regulatory changes affecting these specific products. The stability of the company's supplier relationships, particularly with CIPLA LIMITED, which accounts for 95.5% of its imports, is crucial in mitigating such risks.

2Supply Chain Resilience

Medpro Pharmaceutica's supply chain resilience is closely tied to its primary supplier, CIPLA LIMITED, which accounts for 95.5% of its imports. This heavy reliance on a single supplier may pose risks in the event of supply chain disruptions or regulatory changes affecting CIPLA LIMITED. The company's import portfolio includes 290 unique formulations, indicating a diverse range of products sourced from India. While this diversity may provide some buffer against supply chain disruptions, the concentration of imports from a single supplier suggests that establishing relationships with additional suppliers could enhance supply chain resilience. Ensuring that all suppliers comply with international Good Manufacturing Practices (GMP) and other regulatory standards is essential to maintain product quality and regulatory compliance.

Importing Pharmaceuticals into South Africa — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for South Africa

1Regulatory Authority & Framework

The South African Health Products Regulatory Authority (SAHPRA) is the primary body responsible for regulating the importation, distribution, and sale of medicines in South Africa. SAHPRA operates under the Medicines and Related Substances Act, 101 of 1965, as amended, which provides the legal framework for pharmaceutical regulations in the country. This legislation outlines the requirements for the registration of medicines, importation procedures, and the roles of various stakeholders in the pharmaceutical supply chain. For Indian exporters, understanding SAHPRA's regulatory framework is essential to ensure compliance with South African laws and to facilitate the successful importation of pharmaceutical products.

2Import Licensing & GMP

To import pharmaceutical products into South Africa, companies must obtain the necessary licenses from SAHPRA. This includes a wholesale distribution authorization, which permits the holder to import and distribute medicines within the country. Additionally, all imported medicines must be registered with SAHPRA, ensuring they meet the required safety, efficacy, and quality standards. Indian exporters seeking to supply Medpro Pharmaceutica must ensure that their products are manufactured in facilities compliant with recognized Good Manufacturing Practices (GMP), such as EU GMP, WHO GMP, or PIC/S standards. This compliance is crucial for obtaining the necessary import licenses and for maintaining the quality and safety of the products in the South African market.

Medpro Pharmaceutica Pty Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Medpro Pharmaceutica's product strategy focuses on high-demand therapeutic areas, particularly respiratory and cardiovascular treatments. The company's top five imported products—Salbutamol, Fluticasone, Ipratropium, Salmeterol, and Warfarin—are all essential medications in these categories. The market demand for these products is driven by the prevalence of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), as well as cardiovascular diseases like hypertension and atrial fibrillation. By concentrating on these therapeutic areas, Medpro Pharmaceutica aims to meet critical healthcare needs in South Africa and strengthen its position in the pharmaceutical market.

2Sourcing Profile

Medpro Pharmaceutica's sourcing strategy is centered on importing finished pharmaceutical formulations from India, with a particular emphasis on products manufactured by CIPLA LIMITED. This focus allows the company to leverage CIPLA LIMITED's extensive product portfolio and established reputation for quality. The preference for finished formulations over raw active pharmaceutical ingredients (APIs) enables Medpro Pharmaceutica to streamline its operations and ensure the availability of ready-to-use medicines in the South African market. Indian exporters seeking to supply Medpro Pharmaceutica should ensure that their products meet the necessary quality standards and regulatory requirements to align with the company's sourcing profile.

Seller's Guide — How to Become a Supplier to Medpro Pharmaceutica Pty Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the South African market through partnerships with Medpro Pharmaceutica. The company's focus on high-demand therapeutic areas presents a potential avenue for suppliers offering complementary products. However, to capitalize on this opportunity, Indian exporters must ensure that their products meet SAHPRA's regulatory requirements, including GMP compliance and appropriate labeling. Additionally, establishing a reliable supply chain and maintaining consistent product quality are essential to building a successful partnership with Medpro Pharmaceutica.

2Requirements & Qualifications

Indian exporters seeking to supply Medpro Pharmaceut

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Medpro Pharmaceutica Pty Limited

What products does Medpro Pharmaceutica Pty Limited import from India?

Medpro Pharmaceutica Pty Limited imports 13 pharmaceutical products across 7 categories. Top imports: Salbutamol ($10.5M), Fluticasone ($6.7M), Ipratropium ($1.9M), Salmeterol ($1.4M), Warfarin ($1.2M).

Who supplies pharmaceuticals to Medpro Pharmaceutica Pty Limited from India?

Medpro Pharmaceutica Pty Limited sources from 4 verified Indian suppliers. The primary supplier is Cipla Limited (95.5% of imports, $12.9M).

What is Medpro Pharmaceutica Pty Limited's total pharmaceutical import value?

Medpro Pharmaceutica Pty Limited's total pharmaceutical import value from India is $24.1M, based on 520 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Medpro Pharmaceutica Pty Limited focus on?

Medpro Pharmaceutica Pty Limited imports across 7 categories. The largest: Respiratory (85.0%), Cardiovascular (7.7%), Advanced Oncology (2.2%).

Get Full Medpro Pharmaceutica Pty Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 6 company name variants from customs records. For current shipment-level data, contact TransData Nexus.